Vanguard Capital Management
LBRX

Vanguard Capital Management’s LB Pharmaceuticals LBRX Stock Holding History

Vanguard Capital Management’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.5M Buy
971,165
+76,512
+9% +$2.25M ﹤0.01% 2188
2026
Q1 		$22.1M Buy
+894,653
New +$20.6M ﹤0.01% 2288

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management's LBRX Position: Q2 2026 in Review

Vanguard Capital Management increased its LB Pharmaceuticals (LBRX) stake by 8.6% in Q2 2026, buying an estimated $2.25M and bringing the position to 971,165 shares worth $31.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2188.

Vanguard Capital Management first reported a position in LBRX in Q1 2026 and has held it in 2 quarters since. 115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Vanguard Capital Management held 971,165 shares of LB Pharmaceuticals worth $31.5M as of Q2 2026.
  • Vanguard Capital Management bought 76,512 LB Pharmaceuticals shares in Q2 2026, an estimated $2.25M.
  • LB Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2188 holding.
  • Vanguard Capital Management first reported a position in LB Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.